Due to numerous merits, polyesters have been widely used for the preparation of porous scaffolds for biomedical applications. However, insufficient dimensional stability and weak cell interaction are two critical challenges to highly porous polyester scaffolds fulfilling their roles during applications. Here, we report the surface modification of PLGA scaffolds with air plasma for simultaneously tackling the dimensional shrinkage of PLGA scaffolds and improving scaffold–tissue integration. Highly porous PLGA scaffolds with interconnected pore structures and well orientated microtubules were prepared through lyophilization, and an air plasma process with varied duration was applied to the porous scaffolds. Water contact angle measurements indicated that moderate treatment (120 seconds) can significantly increase the wettability without distorting the morphology of and damaging the PLGA scaffolds. Further characterization (SEM, XPS, μ-CT, and theoretical computations) revealed that the plasma treatment enabled the generation of carboxyl groups on the surface of the PLGA scaffold, and the hydrophilic PLGA chain tends to extend under aqueous conditions in comparison to the hydrophobic pristine PLGA chain. Consequently, this could eliminate the hydrophobic-scaffold/water interface and weaken the driving force behind the distortion of the scaffolds in aqueous conditions, and finally inhibit overall shrinkage and maintain the microstructures of the porous scaffolds. Similar results were observed with porous PLA scaffolds, indicating the generality of air plasma treatment in inhibiting the shrinkage of polyester scaffolds. In the meantime, in vitro cell attachment experiments and in vivo subcutaneous implantation results consistently indicated that better maintaining the microstructure could significantly enhance the short-term cell attachment/proliferation on the scaffold and the long-term scaffold–tissue integration. These findings may inspire many creative and efficient strategies for the surface modification of polyester scaffolds to improve their performance for biomedical applications.
The lack of blood compatibility and antifouling ability is still one of the challenges of bare metallic implants and devices for biomedical applications. Here, based on the strong binding affinity of the phosphonic group on metallic substrates and excellent antifouling ability of zwitterionic materials, we reported the rational design of zwitterionic–phosphonic copolymers for efficient antifouling surface modification of diverse biomedical metals. Firstly, nine copolymers with a wide range of mole ratios between the zwitterionic and phosphonic components (from 10 : 90 to 99 : 1) were precisely prepared via conventional radical copolymerization. The XPS result revealed that the copolymers, even if only 1% of the phosphonic component was present, were able to bind onto the titanium alloy substrates. Water contact angle measurement showed that the more zwitterionic component in the coating copolymer, the better the surface wettability of the titanium alloy substrates. Systematic antifouling evaluation (protein adsorption, platelet adhesion, bacterial adhesion, and cell adhesion tests) results consistently indicated that the copolymers bearing the zwitterionic components, ranging from 20 to 95%, can efficiently confer perfect antifouling ability to the titanium alloy substrates, establishing a robust relationship between the composition of the copolymer and the surface antifouling property conferred to the titanium alloy substrates. In addition, the ability of the zwitterionic–phosphonic copolymers to improve the antifouling ability of other biomedical metals (pure Ti and stainless steel) and devices (scalpels) was clearly demonstrated, indicating that the zwitterionic–phosphonic copolymers could serve as general antifouling coating materials for biomedical metals.
In situ mineralized PLGA/PSBMA scaffold enables high-efficiency sustained release of rhBMP-2 (only 1.7% within 35 days) and robust healing of critical-sized (5 mm) nonunion calvarial defects in rats with an ultralow dosage of rhBMP-2 (150 ng per scaffold).